Study Details

Back to Search Results

An Asian study to evaluate efficacy and safety of oral enzalutamide in progressive metastatic prostate cancer participants

Recruitment complete
The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02294461

Astellas Study ID

The unique identification code given by the study sponsor.

9785-CL-0232

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Prostate Cancer

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

18 years - N/A

Sex

Male

Product

enzalutamide

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Apr 2014 - Sep 2023

Masking

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Enrollment number

395

Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for An Asian study to evaluate efficacy and safety of oral enzalutamide in progressive metastatic prostate cancer participants? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

TW00303

Taichung, Taiwan, Province of China

CN00109

Wu Han, China

CN00112

Beijing, China

CN00120

Nanjing, China

TW00309

Kaohsiung, Taiwan, Province of China

KR00209

Seoul, Republic of Korea

KR00202

Seongnam-si, Republic of Korea

CN00113

Shanghai, China

KR00204

Seoul, Republic of Korea

CN00105

Shanghai, China

CN00103

Beijing, China

TW00305

Taoyuan County, Taiwan, Province of China

CN00104

Beijing, China

CN00119

Soochow, China

CN00118

Wenzhou, China

CN00106

Beijing, China

TW00304

Taipei, Taiwan, Province of China

CN00126

Shanghai, China

KR00207

Busan, Republic of Korea

CN00127

Beijing, China

HK00402

Hong Kong, Hong Kong

KR00214

Anyang, Republic of Korea

KR00206

Seoul, Republic of Korea

TW00302

Taichung, Taiwan, Province of China

TW00301

Taipei, Taiwan, Province of China

KR00201

Incheon, Republic of Korea

CN00124

Xi'an, China

KR00210

Seoul, Republic of Korea

KR00215

Seoul, Republic of Korea

KR00203

Daegu, Republic of Korea

CN00125

Tianjin, China

CN00111

Beijing, China

CN00114

Beijing, China

CN00115

Beijing, China

KR00212

Cheongju, Republic of Korea

KR00213

Daejeon, Republic of Korea

TW00308

Tainan, Taiwan, Province of China

TW00306

Taipei, Taiwan, Province of China

CN00121

Changsha, China

CN00110

Nanjing, China

CN00108

Shanghai, China

KR00211

Seoul, Republic of Korea

CN00107

Hangzhou, China

KR00208

Seoul, Republic of Korea

KR00205

Busan, Republic of Korea

TW00307

Tainan, Taiwan, Province of China

CN00102

Shanghai, China

CN00117

Nanjing, China

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo